In8bio, a clinical-stage biopharmaceutical company, has reported its financial performance and business developments in its latest quarterly report. The company, which specializes in the development of gamma-delta T cell therapies for cancer, has not generated revenue as it remains in the clinical trial phase. However, it has outlined significant progress in its clinical programs, including the dosing of patients in a Phase 2 trial for its lead product candidate, INB-400, for glioblastoma treatment. Preliminary data presented at the ASCO Annual Meeting showed promising results, with 92% of patients exceeding median progression-free survival. In8bio has also received Orphan Drug Designation for INB-400 and is planning to submit an IND for an allogeneic arm of INB-400 in 2025. The company's INB-100 trial for...Show More

In8bio, a clinical-stage biopharmaceutical company, has reported its financial performance and business developments in its latest quarterly report. The company, which specializes in the development of gamma-delta T cell therapies for cancer, has not generated revenue as it remains in the clinical trial phase. However, it has outlined significant progress in its clinical programs, including the dosing of patients in a Phase 2 trial for its lead product candidate, INB-400, for glioblastoma treatment. Preliminary data presented at the ASCO Annual Meeting showed promising results, with 92% of patients exceeding median progression-free survival. In8bio has also received Orphan Drug Designation for INB-400 and is planning to submit an IND for an allogeneic arm of INB-400 in 2025. The company's INB-100 trial for high-risk leukemias has completed primary enrollment, with encouraging relapse-free survival data. In8bio's preclinical programs, including INB-300, are advancing, with plans to move towards animal models and potentially IND enabling studies. The company has expanded its DeltEx platform capabilities to include iPSC derived gamma-delta T cells, with promising preclinical data presented at various medical meetings. In8bio's financial condition indicates that its existing cash will fund operations into January 2025, with plans to raise additional capital through equity and/or debt offerings, strategic collaborations, or licensing arrangements. The company's operating lease commitments and material cash requirements have been disclosed, with a focus on continuing clinical development and seeking potential collaborative partners.